News FDA rejects Mylan and Biocon biosimilar, citing manufacturin... Neulasta biosimilar hits trouble with regulators because of manufacturing issues
News Payday for AbbVie as Humira biosimilar delayed for five year... Deal with Amgen signals exclusivity until 2023 for mega-blockbuster
News Ready to pounce: Samsung joins Amgen with Humira biosimilar ... No-one can launch biosimilars until patent expires next year
News Roche's Herceptin facing further biosimilar threats in US Breast cancer blockbuster facing potential trio of US competitors.
News FDA rejects Amgen/UCB osteoporosis drug The FDA has rejected Amgen and UCB’s Evenity (romosozumab) osteoporosis drug after a late-stage trial unexpectedly highlighted a potential cardiac safety risk.
News Biosimilars manufacturers close in on Roche cancer blockbust... FDA panel backs Herceptin and Avastin biosimilars.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
